Med Spa M&A in 2025-2026: Valuations, Deal Structures, and What’s Next
Turn adjusted EBITDA and a few practice details into a directional enterprise-value range with our Healthcare Practice Valuation Calculator. Educational and directional, and no email required.
Private equity investment in medical spas remained disciplined in 2025, with add-on acquisitions dominating over headline deals and valuations ranging from 3x to 6x EBITDA for smaller practices to 7x to 12x EBITDA for regional platforms exceeding $20M revenue. Deal structures typically split 60 to 80 percent cash at close with 20 to 40 percent rollover equity, with holdbacks common where provider retention or growth execution is uncertain. The 2026 market is closely watching the recapitalization cycle of major PE-backed medspa platforms, which could trigger renewed acquisition intensity and upward multiple pressure across the sector. Buyers now prioritize recurring revenue, EBITDA margins, clean financial reporting, and teams that operate independently of a single owner. Compliance documentation around scope of practice and MSO structures has become a deal prerequisite. Written by Tommy Newton, Principal, Xite.
For medspa operators and PE sponsors tracking the aesthetics rollup market, the pending recapitalization of major platforms in 2026 could reset valuation benchmarks and deal pace across the sector. Understanding current deal structure norms is essential for operators considering a partnership or exit process.
While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.